Vivos Therapeutics, Inc.

NasdaqCM:VVOS Stock Report

Market Cap: US$23.3m

Vivos Therapeutics Management

Management criteria checks 4/4

Vivos Therapeutics' CEO is R. Huntsman, appointed in Sep 2016, has a tenure of 8.25 years. total yearly compensation is $657.70K, comprised of 70.5% salary and 29.5% bonuses, including company stock and options. directly owns 1.51% of the company’s shares, worth $351.42K. The average tenure of the management team and the board of directors is 2.9 years and 4.5 years respectively.

Key information

R. Huntsman

Chief executive officer

US$657.7k

Total compensation

CEO salary percentage70.5%
CEO tenure8.3yrs
CEO ownership1.5%
Management average tenure2.9yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Nov 12
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Sep 10
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Apr 25
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Apr 18
Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Vivos Therapeutics again delays Q2 2022 results

Aug 23

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Jun 29

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

May 21
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

Vivos Therapeutics: First Take After The Broad Market Sell-Off

Mar 06

CEO Compensation Analysis

How has R. Huntsman's remuneration changed compared to Vivos Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$13m

Jun 30 2024n/an/a

-US$12m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$658kUS$463k

-US$14m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022US$938kUS$385k

-US$24m

Sep 30 2022n/an/a

-US$25m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$1mUS$344k

-US$20m

Sep 30 2021n/an/a

-US$24m

Jun 30 2021n/an/a

-US$21m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$455kUS$252k

-US$18m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$11m

Mar 31 2020n/an/a

-US$12m

Dec 31 2019US$328kUS$249k

-US$12m

Dec 31 2018US$284kUS$249k

-US$9m

Compensation vs Market: R.'s total compensation ($USD657.70K) is about average for companies of similar size in the US market ($USD650.00K).

Compensation vs Earnings: R.'s compensation has been consistent with company performance over the past year.

CEO

R. Huntsman (66 yo)

8.3yrs

Tenure

US$657,701

Compensation

Mr. R. Kirk Hunstman is the Co-Founder of Vivos Therapeutics, Inc. since September 2016 and has been its Chief Executive Officer and Director since September 2016 and has been its Chairman of the Board sin...

Leadership Team

NamePositionTenureCompensationOwnership
R. Huntsman
Co-Founder8.3yrsUS$657.70k1.51%
$ 351.4k
Bradford Amman
CFO, Treasurer & Secretary6.2yrsUS$400.04k0.0016%
$ 383.8
Todd Huntsman
Co-Founder & Senior VP of Product and Technologyless than a yearno datano data
RaeAnn Byrnes
Co-Founder and Senior VP of Events & Clinical Advisory Servicesno datano datano data
Susan McCullough
Co-Founder & Executive VP of Operationsless than a yearno datano data
Nicholas DeGennaro
Senior Vice President of Medical Integration Division5.2yrsno datano data
Ruth Hembree
Senior Vice President of Practice Servicesno datano datano data
Stephanie Huebner
Senior Vice President of Dental Service Integration2.9yrsno datano data
John Ballard
Senior Vice President of Technologyless than a yearno datano data

2.9yrs

Average Tenure

Experienced Management: VVOS's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
R. Huntsman
Co-Founder8.3yrsUS$657.70k1.51%
$ 351.4k
Leonard Sokolow
Independent Director4.5yrsUS$63.00k0.0083%
$ 1.9k
Anja Krammer
Independent Director4.5yrsUS$58.00k0%
$ 0
Mark Lindsay
Independent Director4.5yrsUS$58.00k0%
$ 0
Matthew Thompson
Independent Director4.5yrsUS$63.00k0%
$ 0
Edward Zuckerberg
Member of Medical & Clinical Advisory Board3.9yrsno datano data
Ralph Green
Independent Director4.5yrsUS$58.00k0%
$ 0
Michael Gelb
Member of Medical & Clinical Advisory Board3.9yrsno datano data
Manisha Witmans
Member of Medical & Clinical Advisory Board3.9yrsno datano data
Tammarie Heit
Member of Medical & Clinical Advisory Board3.9yrsno datano data
Clete Kushida
Co-Chair of Medical & Clinical Advisory Board3.9yrsno datano data
Cecilia Wu
Co-Chair of Medical & Clinical Advisory Boardno datano datano data

4.5yrs

Average Tenure

64yo

Average Age

Experienced Board: VVOS's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 05:37
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vivos Therapeutics, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
Edward WooAscendiant Capital Markets LLC
Lucas WardAscendiant Capital Markets LLC